Cover Image
市場調查報告書

EpiCast Report:血脂異常症的流行病學的預測

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025

出版商 GlobalData 商品編碼 262489
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:血脂異常症的流行病學的預測 EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025
出版日期: 2016年12月01日 內容資訊: 英文 61 Pages
簡介

本報告提供全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、中國 (都市區))的血脂異常症的發病情形與今後預測相關分析,血脂異常症的特徵和全世界的發病情形,今後10年的發病數量的預測值,各國、各症狀的詳細趨勢等調查評估。

第1章 目錄

第2章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全世界的趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 血脂異常症的流行病學的預測 (今後11年份)
    • 血脂異常症
    • 家族性高膽固醇血症
    • 高LDL膽固醇血症
    • 高甘油三酯血症
    • 超高甘油三酯血症
    • 低HDL膽固醇血症
  • 議論
    • 流行病學的趨勢相關考察
    • 分析的限制
    • 分析的優勢

第3章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER137-16

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease (CVD), and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial.

The clinical diagnostic criteria for dyslipidemia and serum lipid abnormalities vary across countries and depend on the disease treatment and management guidelines that are followed in each country. Guidelines for the detection, evaluation, treatment, and management of dyslipidemia, as well as the prevention of associated CVD, are updated periodically, which has led to further differences over the past several decades in how the prevalence of dyslipidemia is assessed in different studies. For this analysis, GlobalData epidemiologists estimated the total prevalent cases of serum lipid abnormalities according to country-specific cut-offs.

In 2015, there were 580,825,262 total prevalent cases of dyslipidemia in the 8MM. This is forecast to grow to 680,288,645 by 2025, at an Annual Growth Rate (AGR) of 1.71%. Urban China made up the majority of the total prevalent cases in the 8MM throughout the forecast period, and will also experience the highest growth from 274,741,284 total prevalent cases of dyslipidemia in 2015 to 348,184,445 cases by 2025, at an AGR of 2.67%. The US is forecast to grow at an AGR of 1.34%, from 133,104,335 total prevalent cases of dyslipidemia in 2015 to 150,918,348 cases by 2025. In the 8MM, there were 317,925,626 diagnosed prevalent cases of dyslipidemia, which is forecast to grow to 370,440,489 by 2025.

GlobalData epidemiologists used comprehensive, country-specific data from population-based national health surveys, such as the NHANES in the US and the CHNS in urban China. Additionally, data from peer-reviewed journal articles were utilized to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, as well as other therapeutically significant patient populations including the diagnosed prevalent cases of dyslipidemia and the total prevalent cases of FH.

Scope

  • The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of dyslipidemia-which are defined as elevated low-density lipoprotein cholesterol (LDL-C), high triglycerides (TG), or low levels of high-density lipoprotein cholesterol (HDL-C)-as well as the total prevalent cases of increased LDL-C, and very high TG, segmented by sex and age. Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) and very high TG in these markets.
  • The dyslipidemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Dyslipidemia EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
  • Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.
  • Understand the distribution of types of dyslipidemia and FH in these markets.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global Trends
  • 2.4 Forecast Methodology
    • 2.4.1 Sources Used Tables
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Sources Not Used
  • 2.5 Epidemiological Forecast for Dyslipidemia (2015-2025)
    • 2.5.1 Dyslipidemia
    • 2.5.2 Familial Hypercholesterolemia
    • 2.5.3 Increased Low-Density Lipoprotein Cholesterol
    • 2.5.4 High Triglycerides
    • 2.5.5 Very High Triglycerides
    • 2.5.6 Low High-Density Lipoprotein Cholesterol
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 Limitations of the Analysis
    • 2.6.3 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologists
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
  • 3.3 About GlobalData
  • 3.4 About EpiCast
  • 3.5 Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Dyslipidemia
  • Table 2: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia
  • Table 3: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH
  • Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C
  • Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG
  • Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C
  • Table 7: 8MM, Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 8: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 9: 8MM, Total Prevalent Cases of Increased LDL-C, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025
  • Table 10: 8MM, Total Prevalent Cases of High TG, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025
  • Table 11: 8MM, Total Prevalent Cases of Very High TG, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025
  • Table 12: 8MM, Total Prevalent Cases of Low HDL-C, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025

List of Figures

  • Figure 1: 8MM Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, 2015-2025
  • Figure 2: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, 2015-2025
  • Figure 3: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages ≥20 Years, N, 2015 and 2025
  • Figure 4: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, N, 2015 and 2025
  • Figure 5: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 6: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, 2015
  • Figure 7: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages ≥20 Years, 2015
  • Figure 8: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 9: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 10: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, 2015
  • Figure 11: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages ≥20 Years, 2015
  • Figure 12: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 13: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 14: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages ≥20 Years, N, 2015
  • Figure 15: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ≥20 Years, 2015
  • Figure 16: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages ≥20 Years, 2015
Back to Top